Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years.
As published in the journal Cell, a research team has developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during "targeted therapy" treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by the team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Mechanistically, CKIα ablation induces p53 activation, and CKIα degradation underlies the therapeutic effect of lenalidomide in a pre-leukemia syndrome. Authors describe the development of CKIα inhibitors, which co-target the transcriptional kinases CDK7 and CDK9, thereby augmenting CKIα-induced p53 activation and its anti-leukemic activity.
Oncogene-driving super-enhancers (SEs) are highly sensitive to CDK7/9 inhibition. Researchers identified multiple newly gained SEs in primary mouse acute myeloid leukemia (AML) cells and demonstrate that the inhibitors abolish many SEs and preferentially suppress the transcription elongation of SE-driven oncogenes.
Authors show that blocking CKIα together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferation-maintaining SE-driven oncogenes, and induce apoptosis. Leukemia progenitors are selectively eliminated by the inhibitors, explaining their therapeutic efficacy with preserved hematopoiesis and leukemia cure potential; they eradicate leukemia in cell culture and AML mouse models and in several patient-derived AML xenograft models, supporting their potential efficacy in curing human leukemia.
"We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice's' leukemia signs disappeared overnight," shared the senior author.
BioTheryX recently bought the rights to this promising drug from HU's technology transfer company Yissum. Together with Ben-Neriah's research team, they are now applying for FDA approval for phase I clinical studies.
https://www.cell.com/cell/fulltext/S0092-8674(18)30973-5
https://www.eurekalert.org/pub_releases/2018-08/thuo-fft082418.php
Small molecule inhibitor targets several proteins to cure for acute leukemia
- 1,796 views
- Added
Edited
Latest News
Circadian rhythms can influ…
By newseditor
Posted 27 Apr
With hybrid brains, these m…
By newseditor
Posted 27 Apr
Blocking activation of NF-κ…
By newseditor
Posted 27 Apr
Vitamin D regulates microbi…
By newseditor
Posted 27 Apr
Role of alternative splicin…
By newseditor
Posted 27 Apr
Other Top Stories
Purkinje cell misfiring generates high-amplitude action tremors
Read more
Dads low protein diet affects health of future offspring
Read more
A new antidepressant binding to allosteric site of serotonin transp…
Read more
Retino-Cortical Mapping Ratio Predicts Distinct Cortical Organization
Read more
Key to keep working memory working
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Single dose creatine improv…
By newseditor
Posted 27 Apr
Autonomous circadian rhythm…
By newseditor
Posted 27 Apr
Functional sensory circuits…
By newseditor
Posted 27 Apr
Positive selection CRISPR s…
By newseditor
Posted 27 Apr
Focal clusters of peri-syna…
By newseditor
Posted 27 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar